Role of γ-glutamyl cysteine synthetase (γ-GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias

被引:10
作者
Carnicer, MJ
Bernardini, S
Bellincampi, L
Noguera, NI
Nuccetelli, M
Ammatuna, E
Breccia, M
Lo-Coco, F
Federici, G
机构
[1] Univ Roma Tor Vergata, Dept Internal Med, I-00133 Rome, Italy
[2] Univ Roma Tor Vergata, Dept Lab Med, PTV, I-00133 Rome, Italy
[3] Univ Roma Tor Vergata, Dept Biopathol, PTV, Rome, Italy
[4] Univ Roma La Sapienza, Rome, Italy
[5] IRCCS, Bambino Gesu Hosp, Rome, Italy
关键词
acute myeloid leukemia; acute promyelocytic leukemia; gamma-glutamyl cysteine synthetase; glutathione transferase P1-1;
D O I
10.1016/j.cca.2005.09.012
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Elevated levels of glutathione (GSH) have been reported to play an important role in mediating chemoresistance in tumor cells. The regulation of gamma-glutamylcysteine synthetase (gamma-GCS) is one of the major determinants of GSH homeostasis. The aim of our study was to investigate gamma-GCS gene expression in patients affected by acute myeloid leukemia (AML). Methods: A total of 64 AML samples, including 23 acute promyelocytic leukemia (APL or M3) cases, were included in the study. gamma-GCS mRNA levels were determined by real-time quantitative RT-PCR. All patients were evaluated at diagnosis, whereas post-treatment gamma-GCS mRNA levels were assessed at the end of the consolidation therapy in 16 cases. Results: Our data showed that variable degrees of gamma-GCS expression were detectable in AML, likely reflecting disease heterogeneity; in particular, APL cases, compared to the other AML subsets, showed both significantly lower basal levels of gamma-GCS mRNA at presentation and significantly increased mRNA levels after treatment. Conclusions: Decreased levels of gamma-GCS leading to reduced GSH may at least in part explain the higher sensitivity of APL to chemotherapy. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:342 / 345
页数:4
相关论文
共 15 条
[1]   PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) :620-625
[2]   Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system [J].
Dai, J ;
Weinberg, RS ;
Waxman, S ;
Jing, YK .
BLOOD, 1999, 93 (01) :268-277
[3]   Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines [J].
Davison, K ;
Côté, S ;
Mader, S ;
Miller, WH .
LEUKEMIA, 2003, 17 (05) :931-940
[4]   INVITED COMMENTARY POTENTIAL CONTRIBUTION OF THE GLUTATHIONE-S-TRANSFERASE SUPERGENE FAMILY TO RESISTANCE TO OXIDATIVE STRESS [J].
HAYES, JD ;
STRANGE, RC .
FREE RADICAL RESEARCH, 1995, 22 (03) :193-207
[5]   Hammerhead ribozyme against γ-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins [J].
Iida, T ;
Kijima, H ;
Urata, Y ;
Goto, S ;
Ihara, Y ;
Oka, M ;
Kohno, S ;
Scanlon, KJ ;
Kondo, T .
CANCER GENE THERAPY, 2001, 8 (10) :803-814
[6]  
LIVAK K, 1997, USER B, V2
[7]  
Mandelli F, 1997, BLOOD, V90, P1014
[8]  
Mäntymaa P, 2000, HAEMATOLOGICA, V85, P238
[9]  
O'Brien M, 2000, J PHARMACOL EXP THER, V294, P480
[10]   Cellular mechanisms of resistance to chronic oxidative stress [J].
Sagara, Y ;
Dargusch, R ;
Chambers, D ;
Davis, J ;
Schubert, D ;
Maher, P .
FREE RADICAL BIOLOGY AND MEDICINE, 1998, 24 (09) :1375-1389